Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 77.61

+3.5%

Nov 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2141)	2/11/2008 12:35:22 PM
From: Jibacoa	Read Replies (1) of 3722

ASTM is still trying to get off the DT coming frpm its Oct 4 H at $1.43 It is up 6.92% on volume of 195,690 about 1/6 of its ADV. bigcharts.marketwatch.com On Friday it reported results for the 2ndQ & some "clinical achievements",including: The 1st cardiac patient treated with its autologous stem cell therapy for dilated cardiomyopathy. The first human application of its CRC product to regenerate damaged heart tissue. Promising interim results from the first 13 patients treated in a PI/II in Germany to evaluate the safety of VRCs, in the treatment of chronic diabetic foot wounds associated with schemia.(12 months post-treatment, all patients who were treated with VRCs reported no major amputations,no cell-related adverse events and healing of all open wounds.) Results from the 1st use of BRCs to treat 4 patients with osteonecrosis of the femoral head in Germany.(All patients tolerated the procedure well & have reported reduction in hip pain with no signs of disease progression, & were back to work within 6 months after treatment.) Results of the PI/II in the US to collect safety & efficacy data using BRCs to treat severe non-union fractures.(Of 36 patients treated,33 completed the 12months follow-up & an overall 91% healing rate was observed.) But in spite of the encouraging progress in their clinical development programs, revenues for the Q were down 50% vs. 2007 results.($84,000 vs. $158,000 in 2007.) Expenses for the Q increased to $5.621M vs. $4.898M in 2007.The loss for the Q was $5.172M ($.04/shr) vs. $4.225M ($.04/shr) in 2007. At the end of the Q,it had $31.2M in cash,vs. $28.3M at the end of the fiscal Yr. in Jun 2007.It expects a burn rate about $1.8M/month in 2008. The stock needs to close above the resistance at the $0.75 level before it can test the more important looking at $0.85 <g> The "analysts" have a consensus target for ASTM around $1.75 & it seems that with some good reports & a better market environment it could get to the $2 level.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next